Oragenics (OGEN) Depreciation & Amortization (CF) (2010 - 2023)
Oragenics' (OGEN) quarterly Depreciation & Amortization (CF) came in at $4785.0 in Q3 2023, down 62.46% YoY from $12747.0 in Q3 2022, and down 57.67% on a QoQ basis from $11303.0 in Q2 2023.
Oragenics (OGEN) Depreciation & Amortization (CF) (2010 - 2023) Analysis & Trends
Oragenics (OGEN) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $4785.0 in Q3 2023.
- Quarterly Depreciation & Amortization (CF) fell 62.46% year-over-year to $4785.0 in Q3 2023, while the trailing twelve-month figure through Jun 2024 was $4785.0 (down 90.12% YoY) and the FY2023 annual result came in at $27391.0, down 38.68% from the prior year.
- Depreciation & Amortization (CF) fell to $4785.0 in Q3 2023, from $11303.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $18278.0 in Q4 2019 to a low of $4785.0 in Q3 2023.
- A 5-year average of $11980.1 and a median of $12747.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2019 — Depreciation & Amortization (CF) soared 302.84% — and 2023, when it sank 62.46%.
- Tracing OGEN's Depreciation & Amortization (CF) over 5 years: stood at $18278.0 in 2019, then retreated by 29.65% to $12858.0 in 2020, then plunged by 50.07% to $6420.0 in 2021, then soared by 103.63% to $13073.0 in 2022, then tumbled by 63.4% to $4785.0 in 2023.
- The last three Depreciation & Amortization (CF) figures came in at $4785.0 (Q3 2023), $11303.0 (Q2 2023), and $11303.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 4,785.00 |
| Sep 30, 2023 | 4,785.00 |
| Jun 30, 2023 | 11,303.00 |
| Jun 30, 2023 | 11,303.00 |
| Mar 31, 2023 | 11,303.00 |
| Mar 31, 2023 | 11,303.00 |
| Dec 31, 2022 | 13,073.00 |
| Dec 31, 2022 | 13,073.00 |
| Sep 30, 2022 | 12,747.00 |
| Sep 30, 2022 | 12,747.00 |
| Jun 30, 2022 | 10,379.00 |
| Jun 30, 2022 | 10,379.00 |
| Mar 31, 2022 | 8,468.00 |
| Mar 31, 2022 | 8,468.00 |
| Dec 31, 2021 | 6,420.00 |
| Dec 31, 2021 | 6,420.00 |
| Sep 30, 2021 | 9,641.00 |
| Sep 30, 2021 | 9,641.00 |
| Jun 30, 2021 | 12,451.00 |
| Jun 30, 2021 | 12,451.00 |